CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.48B, above the global median of $1.15B
- FinancialsAltman Z-Score 14.53: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
3.53%Above 5Y avg (3.34%)
Annual Rate
CNY 0.30Paid annual
Payout Ratio
40.3%Sustainable
Payback Period
27.0 yr
Last Ex-Dividend
Jun 5, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
16.65BCNY2.48B · vs all stocks (USD)
Trailing P/E
13.48xRevenue (TTM)
3.04BCNY452.58M · vs all stocks (USD)
Profit Margin
40.63%Beta
0.1410xvs all stocks
52-Week Change
0.47%vs all stocks
Market Capitalization
16.65BCNY2.48B · vs all stocks (USD)
Enterprise Value
15.43BCNY2.29B · vs all stocks (USD)
Trailing P/E
13.48xForward P/E
23.22xPrice to Sales (TTM)
5.38xPrice to Book (MRQ)
2.26xEnterprise to Revenue
5.07xEnterprise to EBITDA
16.60xGross Margin
71.62%Profit Margin
40.63%Operating Margin
21.19%Return on Assets (TTM)
5.13%Return on Equity (TTM)
17.63%Revenue (TTM)
3.04BCNY452.58M · vs all stocks (USD)
Revenue per Share (TTM)
1.49CNYUpdated Aug 20, 2026Quarterly Revenue Growth
14.80%Gross Profit (TTM)
2.14BCNY318.96M · vs all stocks (USD)
EBITDA (TTM)
1.96BCNY291.37M · vs all stocks (USD)
Net Income (TTM)
1.24BCNY183.91M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
16.20%Operating Cash Flow (TTM)
853.07MCNY126.86M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
371.43MCNY55.23M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
3.53%vs all stocks
5-Year Average Dividend Yield
3.34%vs all stocks
Payout Ratio
40.32%Minority Interest (Equity)
4.42MCNYFY2025 · Dec 31, 2025Revenue
2.95BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
874.50MCNYFY2025 · Dec 31, 2025Gross Profit
2.07BCNYFY2025 · Dec 31, 2025Operating Income
602.84MCNY89.65M · vs all stocks (USD)
Pre-tax Income
1.48BCNYFY2025 · Dec 31, 2025Income Tax Expense
280.05MCNYFY2025 · Dec 31, 2025Net Income
1.20BCNYFY2025 · Dec 31, 2025EBIT
1.50BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.96BCNYFY2025 · Dec 31, 2025Research & Development
167.12MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
787.68MCNYFY2025 · Dec 31, 2025Other Operating Expenses
28.25MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
3.91MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.81MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.6200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.6200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.97BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.97BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.20BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
21.86MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.43BCNYFY2025 · Dec 31, 2025Free Cash Flow
910.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.43BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.20BCNYFY2025 · Dec 31, 2025Other Non-cash Items
51.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
85.45MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
92.33MCNYFY2025 · Dec 31, 2025Capital Expenditures
-516.49MCNYFY2025 · Dec 31, 2025Purchase of Investments
-259.53MCNYFY2025 · Dec 31, 2025Sale of Investments
1.56BCNYFY2025 · Dec 31, 2025Other Investing Activity
-44.37KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
785.13MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
473.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-648.90MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-505.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
41.74MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-639.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.96BSharesUpdated Aug 20, 2026Float Shares
1.05BSharesUpdated Aug 20, 2026% Held by Insiders
34.08%vs all stocks
% Held by Institutions
15.98%vs all stocks
Total Cash (MRQ)
1.81BCNY268.46M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9230CNYUpdated Aug 20, 2026Total Debt (MRQ)
683.56MCNY101.65M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0944xCurrent Ratio (MRQ)
4.84xBook Value per Share (MRQ)
3.70CNYUpdated Aug 20, 2026Total Assets
7.91BCNY1.18B · vs all stocks (USD)
Total Current Assets
2.75BCNYFY2025 · Dec 31, 2025Total Liabilities
798.84MCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.16BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
253.33MCNYFY2025 · Dec 31, 2025Total Current Liabilities
545.51MCNYFY2025 · Dec 31, 2025Cash
1.43BCNYFY2025 · Dec 31, 2025Cash Equivalents
8.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.43BCNYFY2025 · Dec 31, 2025Other Short-term Investments
63.22MCNYFY2025 · Dec 31, 2025Accounts Receivable
409.02MCNYFY2025 · Dec 31, 2025Inventory
704.22MCNYFY2025 · Dec 31, 2025Accounts Payable
91.10MCNYFY2025 · Dec 31, 2025Short-term Debt
308.37MCNYFY2025 · Dec 31, 2025Other Current Liabilities
11.65MCNYFY2025 · Dec 31, 2025Long-term Debt
217.52MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.96BCNYFY2025 · Dec 31, 2025Retained Earnings
3.89BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
7.11BCNY1.06B · vs all stocks (USD)
Treasury Stock
88.11MCNYFY2025 · Dec 31, 202552-Week Low
7.16CNYUpdated Aug 20, 202652-Week High
10.67CNYUpdated Aug 20, 202652-Week Change
0.47%vs all stocks
Beta
0.1410xvs all stocks
50-Day MA
8.07CNYUpdated Aug 20, 2026200-Day MA
8.69CNYUpdated Aug 20, 2026Avg 10-Day Volume
37.42MSharesUpdated Aug 20, 2026Avg 30-Day Volume
34.45MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
0.6200CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 14.53: safe zoneNotable
Altman Z-Score: 14.53
High structural barrier to entryNotable
Barrier to Entry: 0.58
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.48B, above the global median of $1.15BNotable
Market cap (USD): 2,475,666,686.119Global Median: 1,146,734,693.424
Levered free cash flow is $55.23M, above the global median of $16.24MNotable
Levered free cash flow (USD): 55,234,705.735Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hubei Jumpcan Pharmaceutical Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
CIE Automotive India Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Manhattan Associates Inc.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities